Inhalation drug delivery devices
Hovione identified the need to develop its own inhaler device portfolio integrated within our inhalation drug product development services. This approach enables us to serve our business partners’ needs better. Hovione’s inhaler portfolio has been developed to address specific target product profiles, while bearing in mind the following factors: maximizing simplicity of use and maximizing industrial manufacturability. As a result, Hovione’s inhalers exhibit the lowest number of parts and an absence of metal needles, springs or blades, making them highly competitive in the global market.
The present portfolio is structured to address two main areas of therapeutic intervention: acute treatment and chronic treatment.
For acute or short term treatments, Hovione offers TwinCaps, the world’s first market approved, single use, disposable inhaler. This factory filled, cavity-based device allows the effective delivery of up to 50 mg of powder per cavity. TwinCaps in on sale in Japan, as part of DaiiChi Sankyo's influenza product Inavir®.
For chronic or long term treatments, Hovione offers PowdAir, a simple, reusable, capsule based (size 3 HPMC) metal-less inhaler.